Compare Nova Ltd (NVMI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nova Ltd vs TG Therapeutics Inc — how do they compare? Nova Ltd trades at $352.85 (market cap $11.28B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Nova Ltd is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Nova Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nova Ltd for 4 Days and TG Therapeutics Inc for 16 Days on average.
| NVMI | TGTX | |
|---|---|---|
Market Cap | $11.28B | $8.16B |
Volume | 394,997 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $605.65 | $59.06 |
52-Week Low | $275.78 | $26.94 |
Typical Hold Time | 4 Days | 16 Days |
Enterprise Value | $11.06B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nova Ltd
Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
